NICE ruling on prostate cancer drug questioned

cancer reaserch

Scientists have expressed their disappointment over a preliminary decision by the National Institute of Health and Care Excellence not to offer a life-extending drug to prostate cancer patients until after they have received chemotherapy.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here